Please login to the form below

Not currently logged in
Email:
Password:

Porter Novelli appoints Sally Ward as MD

PR agency Porter Novelli has appointed Sally Ward as partner and managing director of its operations in the UK

PR agency Porter Novelli has appointed Sally Ward as partner and managing director of its operations in the UK. Ward replaces Jean Wyllie, who announced her departure from the agency late last year.

Ward was previously founder and director of Plum Consulting, an executive search, talent management and senior-level coaching and mentoring firm. Prior to this she spent five years with Weber Shandwick UK; and before then seven years with Porter Novelli (known then as Countrywide Porter Novelli) as a portfolio director and later as the agency's UK development director.

 

Sally Ward
Sally Ward

 

"We are delighted to welcome Sally back to the agency," said Gary Stockman, CEO, Porter Novelli. "She is an extremely well-respected leader in the industry with a 20-year track record of growing business both domestically and across borders. Her emphasis and personal commitment to attracting and developing talent will be especially valuable."

Ward said: "Taking on this role was a challenge that I couldn't resist. Porter Novelli remains a strong brand synonymous with quality work, and I look forward to helping to grow its position in the marketplace. Addressing that will be exciting, as will the opportunity to build an industry-leading team."

In addition to her roles as UK MD and partner, Ward will join Porter Novelli's executive committee.
 

28th January 2010

Share



Related Hub content

    Your search did not contain any words. Please try again.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
McCann Complete Medical

Complete Medical delivers world-class solutions in medical communications, regulatory services, market access, healthcare digital excellence, and strategic consultancy. We bring...

Latest intelligence

England’s clinical commissioning landscape
Who are the real masters in the new NHS?...
How will the new landscape of Hep C treatments affect patients?
The development of new therapeutic agents is set to transform the treatment of hepatitis C over the coming years....
Pharma deal watch - handshake
Pharma deals during March 2014
Deal Watch: Major pharma collaborations, acquisitions and agreements in the past month...